Neuren Pharmaceuticals Ltd has released a press release.
Update on development plan for NNZ-2591
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neurens Rett syndrome Phase 2 trial published in Neurology
- Preliminary Final Report and statutory accounts
- NNZ-2591 positive effects in Phelan-McDermid syndrome model
- Trofinetide ex-North America exclusive negotiation period
- Neuren and Lanstead agree to pause settlements for 120 days
Later from Neuren Pharmaceuticals
- NNZ-2591 positive effects in Angelman syndrome model
- NNZ-2591 positive effects in Pitt Hopkins syndrome model
- Neuren approaching key milestones in Q4 2019
- FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
- FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals